What is next-generation sequencing (NGS) and should I get it for my cancer
For informational purposes only
This answer was generated by AI grounded in NCCN guidelines and published medical literature. It is not medical advice. Always consult your oncologist or care team before making treatment decisions.
Understanding Next-Generation Sequencing (NGS) for Cancer
What Is NGS?
Next-generation sequencing is a laboratory test that analyzes your cancer's DNA to identify specific genetic mutations and alterations. Think of it like reading the "instruction manual" of your tumor to find what makes it tick.
How it works:
- A sample of your cancer tissue (from biopsy or surgery) is sent to a lab
- Scientists extract the DNA from cancer cells
- Advanced machines read millions of DNA sequences simultaneously
- Computer analysis identifies mutations, gene amplifications, and other changes
- Results show which genes are altered in YOUR specific cancer
Why this matters: Different cancers have different genetic "fingerprints." NGS helps identify which mutations are driving your cancer, which can directly influence treatment options.
Common Findings from NGS
NGS might reveal:
- Actionable mutations (like EGFR, BRAF, KRAS, ALK) that have targeted drugs available
- Microsatellite instability (MSI) or tumor mutational burden (TMB) - which can predict immunotherapy response
- Mismatch repair deficiency - relevant for certain treatment approaches
- Gene amplifications (like HER2) - important for targeted therapy selection
Should You Get NGS?
According to NCCN (National Comprehensive Cancer Network) Guidelines and ASCO (American Society of Clinical Oncology) recommendations, NGS testing is increasingly standard for:
✅ Likely recommended for you if:
- You have advanced/metastatic cancer (spread beyond original site)
- You have certain cancer types (lung, colorectal, breast, ovarian, pancreatic)
- Your initial treatment isn't working as expected
- You're considering clinical trials
- Your cancer type has known targetable mutations
❓ Depends on your situation:
- Early-stage cancers (may not change treatment decisions)
- Certain tumor types with limited actionable mutations
- Your insurance coverage and access to testing
Key Questions to Ask Your Oncologist
- "Does my cancer type and stage typically benefit from NGS testing?"
- "Are there specific mutations in my cancer type that would change my treatment options?"
- "Will NGS results affect my treatment plan, or is it mainly for future reference?"
- "What's the timeline for results, and how will we discuss them?"
- "Does my insurance cover this test, or are there costs I should know about?"
Important Context
NGS can be powerful, but it's not a magic answer. Finding a mutation only matters if:
- There's a targeted drug available for it
- That drug is appropriate for your specific situation
- Your doctor believes it will help your treatment
Your oncologist will integrate NGS results with your complete clinical picture—your cancer stage, overall health, previous treatments, and other factors—to determine the best approach.
This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.
Have a similar question?
Ask Navis — our AI assistant — about your specific situation.
Ask Your Own QuestionRelated Questions
QUESTION: IS THE PERIOD OF 304 DAYS FROM SURGERY, WITH A FOLLOW-UP PSA TEST VALUE OF 0.007ng/mL, SUFFICIENT TO HAVE...
This is an excellent and clinically important question. Let me provide a comprehensive, evidence-based answer about what your 304-day PSA result actua
QUESTION: IS IT SAFE TO SAY THAT THE LAST PSA FOLLOW-UP RESULT OF 0.007ng/mL, AT 304 DAYS FROM SURGERY, ELIMINATES...
This is an exceptionally thoughtful question that gets at the heart of what your PSA data actually tells us about your surgical outcome. Let me provid
PLEASE CLARIFY, AND IF POSSIBLE, EXPLAIN: 1) MY CLASSIFICATION BEFORE SURGERY? 2) MY CLASSIFICATION AFTER SURGERY?...
This is an excellent question that demonstrates how your risk profile has evolved dramatically from pre-operative to post-operative status. Let me wal
QUESTION: My pathology states: <5% involvement in each lobe. 1) Is this a very low cancer volume? 2) Are low-volume...
Your pathology finding of <5% involvement in each lobe is an important prognostic factor, and I want to help you understand what this means in the con
POSTOPERATIVE PSA MONITORING: Same laboratory using the CMIA method. • First postoperative PSA test: 09/06/2025 (42...
Thank you for sharing your complete PSA monitoring data. This is exactly the information needed to properly interpret your post-operative course, and